Introduction
============

Lung cancer patients make up \~14% of newly diagnosed cancer cases and is the second most widespread cancer worldwide ([@b1-etm-0-0-7958]). Of those, \~85% are non-small cell lung cancer (NSCLC) ([@b2-etm-0-0-7958]). Lung cancer not only has high incidence, but also high death rate. It is a huge healthcare and economic burden for both developing and developed countries.

There are many possible factors that may contribute to the genesis of lung cancer ([@b2-etm-0-0-7958]). Genetics can explain a large proportion of lung cancer occurrence as many single nucleotide polymorphisms have been discovered to be associated with lung cancer susceptibility by genome-wide association studies ([@b3-etm-0-0-7958]). Environment factors, such as air pollution ([@b4-etm-0-0-7958]), particulate matter 2.5 ([@b5-etm-0-0-7958]) and smoking, can facilitate the epigenetic dysfunctions which will interact with genetic changes and trigger tumorgenesis ([@b2-etm-0-0-7958],[@b6-etm-0-0-7958]--[@b9-etm-0-0-7958]). Cigarette smoke includes over 5,000 compounds ([@b10-etm-0-0-7958]), such as nicotine, free radicals, benzopyrene, catechols, polonium-210 and heavy metals ([@b11-etm-0-0-7958]). Many of these compounds are strong carcinogenic chemicals ([@b12-etm-0-0-7958]), which can interfere with DNA mismatch repair and cause somatic mutations. Cigarette smoking accounts for 87% of lung cancer deaths ([@b13-etm-0-0-7958]) and is the leading risk factor.

Unfortunately, the genetic mechanisms of smoking leading to lung carcinogenesis are largely unknown and many observations are contradictory ([@b10-etm-0-0-7958]). For example, benzoapyrene, a carcinogenic chemical from smoke, can induce lung tumors in mice but not in rats ([@b14-etm-0-0-7958]). On the molecular level, several well-established signaling pathways, such as cyclooxygenase and its derived prostanoids, peroxisome proliferator-activated receptor γ and arachidonate 15-lipoxygenase, epidermal growth factor receptor (EGFR) and the P13K/AKT/mTOR and vascular endothelial growth factor-dependent angiogenetic pathway, have been reported to have important roles ([@b10-etm-0-0-7958]). As a complex systems disease ([@b2-etm-0-0-7958]), lung cancer dysfunctions are dynamic and the evolution of smoking-induced lung cancer, i.e. the series of genetic events, can elucidate a more realistic picture of tumorigenesis. With the rapid development of next-generation sequencing, the somatic mutations in cancer patients can be more easily identified. Based on somatic mutation data, the evolutionary trajectories of cancer patients can be reconstructed. Caravagna *et al* ([@b15-etm-0-0-7958]) developed an algorithm called Pipeline for Cancer Inference (PiCnIc) to analyze the colon adenocarcinoma and rectum adenocarcinoma (COAD/READ) somatic mutation data from The Cancer Genome Atlas project. The underlying somatic evolution based on Suppes\' probabilistic causation was reconstructed ([@b16-etm-0-0-7958]) and it was determined that mutations in APC regulator of WNT signaling pathway, KRAS proto-oncogene, and tumor protein p53 were primary events for micro-satellite stable COAD/READ tumors, which was consistent with previous literature. Brown *et al* ([@b17-etm-0-0-7958]), performed phylogenetic analysis on whole-exome sequencing and copy number profiling data of primary and metastatic breast cancer samples and inferred the phylogeny of genomic alterations during breast cancer progression. The study utilized the Dollo parsimony method and the branch and bound exhaustive search algorithm described in Felsenstein ([@b18-etm-0-0-7958]), to reconstruct the phylogenetic tree.

To investigate the genomic alterations triggered by smoking, the present study analyzed the somatic mutations in 100 NSCLC patients. The different genomic alterations amongst non-smokers, ex-smokers and smokers were identified and the most frequent genetic alterations of each smoking subgroup were analyzed to construct oncogenetic trees, which revealed the evolutionary trajectories of smoking NSCLC. The present results provided novel insights into NSCLC development due to smoking and also identified potential intervention targets for treating NSCLC patients.

Materials and methods
=====================

### NSCLC somatic mutation dataset

TRAcking Cancer Evolution through therapy (TRACERx) Consortium is a multi-million pound project funded by Cancer Research UK to better understand the genetic risks of lung cancer through exploring the human genome. The present study obtained the somatic mutation data and smoking status data of 100 NSCLC patients from Jamal-Hanjani *et al* ([@b19-etm-0-0-7958]). The clinical information of these 100 patients are provided in [Table SI](#SD1-etm-0-0-7958){ref-type="supplementary-material"}. The dataset consists of 12 people who never smoked in their life, 48 people who used to smoke but have quit smoking for \>20 years and 40 current smokers or recent ex-smokers. The somatic mutations were annotated to genes. If there were non-synonymous exonic alterations within a gene, this was considered as a mutated gene and it was allocated '1'; otherwise genes were classed as '0'. There were 11,345 genes that were mutated in at least 1 of the 100 NSCLC patients. An 11345×100 matrix was produced where rows denoted genes, the columns were patients and the binary value indicated whether the particular gene was mutated in this patient.

Unlike the TRACERx study by Jamal-Hanjani *et al* ([@b19-etm-0-0-7958]), which analyzed the intratumor heterogeneity by constructing phylogenetic trees for each patient, the present study was interested in characterizing the general mutation pattern within patient subtypes.

### Identifying the mutated genes amongst different smoking status groups

To identify the various mutated genes amongst different smoking status groups, the Fisher\'s Exact Test ([@b20-etm-0-0-7958]) was applied for the confusion table of mutation status and smoking status. P\<0.05 was considered to indicate statistical significance.

### Construction of the evolutionary trajectories for different smoking status groups

How the most frequently mutated genes evolved in different smoking status groups was analyzed using Oncotree ([@b21-etm-0-0-7958],[@b22-etm-0-0-7958]), a widely used method for oncogenetic tree deduction ([@b23-etm-0-0-7958]).

In an oncogenetic tree model, the evolutionary trajectories of tumor genesis are simplified and the causality between genetic alteration events is assumed to occur sequentially. In addition, the causation of a genetic alteration event by another is independent of other causations.

The Oncotree method involves several steps. First, a set of the most relevant genetic events is selected. For the present study, the top 10 most frequent genetic alterations for each smoking status group were considered as relevant for the progression of the tumor group and therefore were selected to be modeled. Then, each pair of such genetic events was assigned a weight corresponding to the probabilities of joint or individual occurrence. Finally, based on the assigned weights, the optimal oncogenetic tree was inferred as maximum-weight branching ([@b21-etm-0-0-7958],[@b22-etm-0-0-7958]).

The method was applied for the present study using R package Oncotree (<http://cran.r-project.org/web/packages/Oncotree/>).

### Annotation of the biological function of the mutated genes

WebGestalt was used to annotate the biological function of the mutated genes ([@b24-etm-0-0-7958]). WebGestalt is a widely used online enrichment tool to model organisms including human, mouse, rat, yeast, fruit fly and *Caenorhabditis elegans*. It has many annotation databases integrated, including Kyoto Encyclopedia of Genes and Genomes, Gene Ontology, DrugBank and Online Mendelian Inheritance in Man. The P-value of overrepresentation enrichment analysis was multiple test-adjusted as the false discovery rate (FDR). In the present study, the enriched categories with FDR\<0.2 were considered as significant.

Results and Discussion
======================

### A total of 68 genes demonstrate different mutation patterns amongst smoking status groups

Fisher\'s exact test was used to identify the different mutated genes amongst the various smoking status groups. A total of 68 gene mutations were considered as significant to smoking status (P\<0.05; [Table I](#tI-etm-0-0-7958){ref-type="table"}). The OncoPrinter plots of these 68 genes in the three different smoking status groups, non-smoker, ex-smoker and smoker, are displayed in [Fig. 1](#f1-etm-0-0-7958){ref-type="fig"}. The genes were ranked based on the mutation frequency in all lung cancer patients. Zinc finger homeobox 4 (ZFHX4), usherin (USH2A), CUB and Sushi multiple domains 1 (CSMD1), CUB and Sushi multiple domains 2 (CSMD2), spectrin α erythrocytic 1 (SPTA1), pappalysin 2 (PAPPA2), dynein axonemal heavy chain 9 (DNAH9), contactin-associated protein like 5 (CNTNAP5), additional sex combs like 3 (ASXL3) were highly mutated in ex-smokers and smokers, but not in non-smokers. The mutation rate was associated the smoking status with the current smokers demonstrating the highest rate of mutated genes. There were several non-smoker specific mutations, such as lysine demethylase 8 (KDM8), zinc finger protein 677 (ZNF677), TEA domain transcription factor 1 (TEAD1) and phosphatidylinositol glycan anchor biosynthesis class M (PIGM). These non-smoker specific mutations suggested that tumorigenesis of lung cancer in non-smoker patients was different from the tumorigenesis of lung cancer in smoking patients.

### Biological functions of the 68 gene mutations associated with smoking status

The 68 gene mutations associated with smoking status were annotated using Gene Ontology (GO) and the biological process (BP), cellular component (CC) and molecular function (MF) categories ([Fig. 2](#f2-etm-0-0-7958){ref-type="fig"}). Numerous genes were annotated to be membrane proteins with biological regulation, metabolic process, and response to stimulus functions ([Fig. 2](#f2-etm-0-0-7958){ref-type="fig"}). These results were expected since smoke is a xenobiotic stimulus to the human body and the chemicals can affect normal metabolic processes, and alter the biological regulations. Rigorous statistical test for the enrichment significance using WebGestalt was performed for deeper investigation into gene function ([@b24-etm-0-0-7958]) with significantly enriched BP ([Table II](#tII-etm-0-0-7958){ref-type="table"}), CC ([Table III](#tIII-etm-0-0-7958){ref-type="table"}) and MF ([Table IV](#tIV-etm-0-0-7958){ref-type="table"}) categories. It was demonstrated that the organ development, morphogenesis of an epithelial fold, muscle tissue morphogenesis and the muscle organ morphogenesis categories were enriched ([Table II](#tII-etm-0-0-7958){ref-type="table"}). These genes may serve an important role in tumor initiation and help transform the normal lung tissue to tumor tissue. Proteins associated with the plasma membrane were enriched ([Table III](#tIII-etm-0-0-7958){ref-type="table"}), which was consistent with the preliminary biological function analysis ([Fig. 2](#f2-etm-0-0-7958){ref-type="fig"}), and indicated that the mutated genes were involved in stimulus response. In addition, enrichment of proteins associated with muscle/fiber functions suggested that the mutated genes may change the lung muscle structure. Significant enrichment of multiple binding functions proved that the mutated genes were key players in signaling transduction and regulation ([Table IV](#tIV-etm-0-0-7958){ref-type="table"}), which may amplify the dysfunctions and accelerate tumorigenesis.

### Evolutionary trajectories of non-smoker, ex-smoker and smoker lung cancer patients

Cancer is a complex multigene and multiprocess disease. The tumorigenesis of colorectal cancer is well studied ([@b25-etm-0-0-7958],[@b26-etm-0-0-7958]) and can be used as a perfect example to explain the roles of mutations in causing pathway dysfunctions. The process includes several steps ([@b25-etm-0-0-7958]): i) Mutation of mismatch-repair (MMR) gene; ii) microsatellite instability (MSI) pathway dysfunction caused by MMR mutation; iii) normal epithelium becomes small adenoma; iv) chromosomal instability and mutations in KRAS and BRAF; v) serrated adenoma pathway dysfunction triggered by BRAF mutation; vi) small adenoma becomes large adenoma; and vii) mutations of PIK3CA, PTEN, tumor protein p53 (TP53), BAX, SMAD4 and transforming growth factor β receptor 2 accelerate the progression from large adenoma to cancer.

Similarly, lung cancer must also have several mutational events, which occur sequentially to initiate and accelerate tumorigenesis. Smoking is a major risk factor that can cause genetic and epigenetic changes that alter the tumorigenesis procedures. Research into this process will help explain the mechanism differences between smoker and non-smoker lung cancer patients.

The Oncotree method was used to produce oncogenetic trees of the top 10 most frequent mutated genes in non-smoker, ex-smoker and smoker lung cancer patients ([Fig. 3](#f3-etm-0-0-7958){ref-type="fig"}). For non-smokers, the early events were EGFR and titin (TTN) mutation. The late EGFR events were mutations of PIGM and zinc finger protein 677, while TTN was followed by mutations of TEAD1, olfactory receptor family 6 subfamily P member 1, catenin β 1, huntingtin interacting protein 1, protocadherin γ subfamily A 8 and SUMO1/sentrin specific peptidase 7. For ex-smokers, TTN was also an early event but more early events were detected compared with non-smokers, including mutations of ryanodine receptor 2, ZFHX4 and CSMD1. For smokers, the results revealed the highest number of early events, including mutations of TTN, ryanodine receptor 2, USH2A, SPTA1 and CSMD1. Results demonstrated that smoking increased spontaneous mutations and formed more complex oncogenetic trees. For non-smokers, EGFR was the primary mutation whilst in ex-smokers and smokers, the importance of TTN was increased. Almost all smokers had the TTN mutation.

### Oncogenetic differences between non-smoker, ex-smoker and smoker lung cancer patients

Based on the oncogenetic trees of non-smoker, ex-smoker and smoker lung cancer patients ([Fig. 3](#f3-etm-0-0-7958){ref-type="fig"}), the key driver gene of non-smoker lung cancer patients was EGFR, whilst the key driver gene of smoker lung cancer patients was TTN.

EGFR is a well-known oncogene that affects the PI3K and RAS pathway and accelerates cell growth and survival ([@b27-etm-0-0-7958]). EGFR is widely expressed in \>60% of NSCLC patients and is a clinically relevant target of tyrosine kinase inhibitors (TKIs). EGFR mutations are more frequent in Asians, females, non-smokers and lung adenocarcinomas ([@b28-etm-0-0-7958],[@b29-etm-0-0-7958]). The present findings determined that EGFR was the key driver gene of non-smoker lung cancer patients which was in agreement with the literature ([@b28-etm-0-0-7958],[@b29-etm-0-0-7958]).

TTN encodes a protein of striated muscle and is the key component for striated muscle assembly and function. TTN mutation is very frequent in the majority of cancer types with the second highest mutation rate behind TP53 in The Cancer Genome Atlas dataset ([@b30-etm-0-0-7958]). In the present study, 65 patients had the TTN mutation and 35 patients did not. For the 65 patients with TTN mutation, there were 2 adenosquamous carcinoma, 2 carcinosarcoma, 31 invasive adenocarcinoma, 1 large cell carcinoma and 29 squamous cell carcinoma patients. For the 35 patients without TTN mutations, there were 1 adenosquamous carcinoma, 30 invasive adenocarcinoma, 1 large cell neuroendocrine and 3 squamous cell carcinoma patients. Although its mechanisms remain largely unknown, TTN has great potential for investigation due to its roles in tumorigenesis and progression ([@b30-etm-0-0-7958]). The present study determined that TTN may function through regulating DNAH9, USH2A, SPTA1 or CSMD2 based on the oncogenetic trees ([Fig. 3](#f3-etm-0-0-7958){ref-type="fig"}). Although the oncogenetic tree only demonstrated the process of genetic alteration occurrence, it provided hints of functional regulations; however, this needs to be further confirmed. To explore the possible regulation mechanisms of TTN, the protein functional association network STRING ([@b31-etm-0-0-7958],[@b32-etm-0-0-7958]) was used with medium confidence (\>0.4). It was determined that TTN can interact with SPTA1 through calmodulin 2 (CALM2) and troponin C1 (TNNC1; [Fig. 4](#f4-etm-0-0-7958){ref-type="fig"}). The STRING confidence scores of each interaction ([Table SII](#SD2-etm-0-0-7958){ref-type="supplementary-material"}) were 0.722 for TTN and CALM2, 0.962 for SPTA1 and CALM2, 0.965 for TTN and TNNC1 and 0.537 for SPTA1 and TNNC1. These results provided insight into how TTN may function in lung cancer of smoking patients, or even other types of cancer.

There were limitations to the oncogenetic tree model. Firstly, the model was based on association rather than causality and the results could not be treated as actual biological regulations, therefore these should be further investigated with experimental methods. Secondly, the oncogenetic tree model cannot handle a large number of genes. The input genes should be carefully picked based on mutation frequency or biological literature with only the highly possible genes analyzed. It is not a general method that can be applied on a genome wide scale. Finally, the sample size should be large enough to capture the association so results generated on small datasets need to be interpreted with caution.

In conclusion, lung cancer is a complex multigene, multiprocess disease with complex genetic and environmental risk factors. Smoking is the biggest risk factor that can alter the genetics and epigenetics of lung tissue causing cancer. Smokers have a much greater chance of developing lung cancer. The present study compared the mutation patterns of non-smoker, ex-smoker and smoker lung cancer patients and identified 68 genes that were significantly differentially mutated amongst smoking status groups. Furthermore, oncogenetic trees were constructed of the top 10 most frequently mutated genes in each group and analyzed. It was identified that in non-smoker lung cancer patients, the key driver gene was EGFR, whilst in smoker lung cancer patients the key driver gene was TTN. The EGFR mutation finding in non-smokers is in line with previous literature. A potential mechanism for the high frequency mutated gene TTN in tumorigenesis was suggested. The present study provided novel insights into the effect of smoking on altering the evolutionary trajectory of lung cancer and its progression.
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![OncoPrinter plot of the 68 mutated genes in non-smokers, ex-smokers and smokers. The genes were ranked by the mutation frequency in all lung cancer patients. ZFHX4, USH2A, CSMD1, CSMD2, SPTA1, PAPPA2, DNAH9, CNTNAP5 and ASXL3 were highly mutated in ex-smokers and smokers but not in non-smokers. Smokers had the highest rate of mutated genes, with smoking status directly correlated with number of mutations. KDM8, ZNF677, TEAD1 and PIGM were non-smoker specific mutations. The different mutation patterns suggested the tumor genesis of non-smoker lung cancer patients was different from the tumor genesis of smoking lung cancer patients. ZFHX4, zinc finger homeobox 4; USH2A, usherin; CSMD1, CUB and Sushi multiple domains 1; CSMD2, CUB and Sushi multiple domains 2; SPTA1, spectrin α erythrocytic 1; PAPPA2, pappalysin 2; DNAH9, dynein axonemal heavy chain 9; CNTNAP5, contactin-associated protein like 5; ASXL3, additional sex combs like 3; KDM8, lysine demethylase 8; ZNF677, zinc finger protein 677; TEAD1, TEA domain transcription factor 1; PIGM, phosphatidylinositol glycan anchor biosynthesis class M.](etm-18-05-3315-g00){#f1-etm-0-0-7958}
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![STRING network of TTN and SPTA1. TTN can interact with SPTA1 through CALM2 and TNNC1. TTN, titin; SPTA1, spectrin α erythrocytic 1; CALM2, calmodulin 2; TNNC1, troponin C1; SPTB, spectrin β erythrocyctic; ANK1, ankyrin 1; DES, desmin; TNNI3, troponin I3; ACTN2, actinin α 2; NEB, nebulin; MYL2, myosin light chain 2; TCAP, titin-cap.](etm-18-05-3315-g03){#f4-etm-0-0-7958}

###### 

A total of 68 genes that demonstrated different mutation patterns amongst non-smokers, ex-smokers and smokers.

  Gene symbol   Gene name                                                                                           NCBI gene ID   Fisher\'s exact test P-value
  ------------- --------------------------------------------------------------------------------------------------- -------------- ------------------------------
  EGFR          Epidermal growth factor receptor                                                                    1956           0.00052
  TTN           Titin                                                                                               7273           0.00071
  ZFHX4         Zinc finger homeobox 4                                                                              79776          0.00433
  USH2A         Usherin                                                                                             7399           0.00549
  SPTA1         Spectrin α, erythrocytic 1                                                                          6708           0.00753
  TRPV6         Transient receptor potential cation channel subfamily V member 6                                    55503          0.00988
  SEC16A        SEC16 homolog A, endoplasmic reticulum export factor                                                9919           0.00988
  SCN1A         Sodium voltage-gated channel α subunit 1                                                            6323           0.01216
  ZNF677        Zinc finger protein 677                                                                             342926         0.01333
  TEAD1         TEA domain transcription factor 1                                                                   7003           0.01333
  PIGM          Phosphatidylinositol glycan anchor biosynthesis class M                                             93183          0.01333
  EPG5          Ectopic P-granules autophagy protein 5 homolog                                                      57724          0.01427
  TENM3         Teneurin transmembrane protein 3                                                                    55714          0.01482
  OR6P1         Olfactory receptor family 6 subfamily P member 1                                                    128366         0.01494
  PAPPA2        Pappalysin 2                                                                                        60676          0.01743
  ZNF783        Zinc finger family member 783                                                                       100289678      0.01769
  CTNNB1        Catenin β 1                                                                                         1499           0.01769
  SPATA13       Spermatogenesis associated 13                                                                       221178         0.01769
  HIP1          Huntingtin interacting protein 1                                                                    3092           0.01769
  SENP7         SUMO1/sentrin specific peptidase 7                                                                  57337          0.01769
  PCDHGA8       Protocadherin γ subfamily A, 8                                                                      9708           0.01769
  SNPH          Syntaphilin                                                                                         9751           0.01769
  ENPEP         Glutamyl aminopeptidase                                                                             2028           0.01819
  KCNH2         Potassium voltage-gated channel subfamily H member 2                                                3757           0.01819
  NLGN3         Neuroligin 3                                                                                        54413          0.01819
  MS4A14        Membrane spanning 4-domains A14                                                                     84689          0.01819
  DEPDC5        DEP domain containing 5                                                                             9681           0.01819
  SMARCA4       SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4   6597           0.02044
  LYST          Lysosomal trafficking regulator                                                                     1130           0.02157
  CNTN4         Contactin 4                                                                                         152330         0.02157
  ZNF536        Zinc finger protein 536                                                                             9745           0.02420
  CNTNAP5       Contactin associated protein like 5                                                                 129684         0.02459
  ASXL3         Additional sex combs like 3, transcriptional regulator                                              80816          0.02459
  DNAH9         Dynein axonemal heavy chain 9                                                                       1770           0.02568
  CNGA2         Cyclic nucleotide gated channel α 2                                                                 1260           0.02841
  KCNH5         Potassium voltage-gated channel subfamily H member 5                                                27133          0.02841
  ZEB2          Zinc finger E-box binding homeobox 2                                                                9839           0.02841
  PHLPP2        PH domain and leucine rich repeat protein phosphatase 2                                             23035          0.02918
  GLI2          GLI family zinc finger 2                                                                            2736           0.02918
  GPR35         G protein-coupled receptor 35                                                                       2859           0.02918
  ATP13A5       Atpase 13A5                                                                                         344905         0.02918
  MYF5          Myogenic factor 5                                                                                   4617           0.02918
  PCDHGB7       Protocadherin γ subfamily B, 7                                                                      56099          0.02918
  WBSCR17       Williams-Beuren syndrome chromosome region 17                                                       64409          0.02918
  BAZ1B         Bromodomain adjacent to zinc finger domain 1B                                                       9031           0.02918
  COL6A5        Collagen type VI α5 chain                                                                           256076         0.03141
  CSMD1         CUB and Sushi multiple domains 1                                                                    64478          0.03183
  RYR2          Ryanodine receptor 2                                                                                6262           0.03217
  TSHZ3         Teashirt zinc finger homeobox 3                                                                     57616          0.03459
  KDM8          Lysine demethylase 8                                                                                79831          0.03728
  NALCN         Sodium leak channel, non-selective                                                                  259232         0.03732
  MALRD1        MAM and LDL receptor class A domain containing 1                                                    340895         0.03732
  DOCK10        Dedicator of cytokinesis 10                                                                         55619          0.03732
  DNAH11        Dynein axonemal heavy chain 11                                                                      8701           0.03857
  TAF1L         TATA-box binding protein associated factor 1 like                                                   138474         0.04006
  PRUNE2        Prune homolog 2                                                                                     158471         0.04006
  PLCH1         Phospholipase C eta 1                                                                               23007          0.04006
  KIAA1549L     KIAA1549 like                                                                                       25758          0.04006
  RPTOR         Regulatory associated protein of MTOR complex 1                                                     57521          0.04165
  CSMD2         CUB and Sushi multiple domains 2                                                                    114784         0.04312
  CDH23         Cadherin related 23                                                                                 64072          0.04357
  KIAA1324L     KIAA1324 like                                                                                       222223         0.04374
  NUP205        Nucleoporin 205                                                                                     23165          0.04374
  TBC1D4        TBC1 domain family member 4                                                                         9882           0.04374
  FLNC          Filamin C                                                                                           2318           0.04717
  CHD7          Chromodomain helicase DNA binding protein 7                                                         55636          0.04717
  DNAH17        Dynein axonemal heavy chain 17                                                                      8632           0.04717

NCBI, National Center for Biotechnology; ID, identification.

###### 

Significantly enriched GO biological process categories of the 68 mutated genes associated with smoking status.

  GO ID        Description                                 P-value       FDR      Overlap genes
  ------------ ------------------------------------------- ------------- -------- --------------------------------------------------------------------------------------------
  GO:0007423   Sensory organ development                   4.48×10^−5^   0.1801   CTNNB1, EGFR, GLI2, MYF5, CHD7, TENM3, CDH23, SMARCA4, USH2A, ZEB2
  GO:0098655   Cation transmembrane transport              0.0001085     0.1801   CNGA2, NALCN, KCNH5, GPR35, ATP13A5, KCNH2, NLGN3, TRPV6, CHD7, RYR2, SCN1A
  GO:0034765   Regulation of ion transmembrane transport   0.0001252     0.1801   NALCN, KCNH5, GPR35, KCNH2, NLGN3, CHD7, RYR2, SCN1A
  GO:0042391   Regulation of membrane potential            0.0001286     0.1801   CNGA2, NALCN, KCNH5, GPR35, KCNH2, NLGN3, RYR2, SCN1A
  GO:0034762   Regulation of transmembrane transport       0.0001394     0.1801   NALCN, KCNH5, GPR35, KCNH2, NLGN3, CHD7, RYR2, SCN1A
  GO:0006812   Cation transport                            0.0001504     0.1801   CNGA2, CTNNB1, NALCN, KCNH5, GPR35, ATP13A5, KCNH2, NLGN3, TRPV6, CHD7, RYR2, SCN1A, CDH23
  GO:0060571   Morphogenesis of an epithelial fold         0.0002124     0.1974   CTNNB1, EGFR, GLI2
  GO:0043010   Camera-type eye development                 0.0002382     0.1974   CTNNB1, EGFR, MYF5, CHD7, TENM3, SMARCA4, ZEB2
  GO:0060415   Muscle tissue morphogenesis                 0.0002664     0.1974   MYF5, CHD7, RYR2, TTN
  GO:0048644   Muscle organ morphogenesis                  0.0002865     0.1974   MYF5, CHD7, RYR2, TTN
  GO:0001508   Action potential                            0.0003213     0.1974   NALCN, GPR35, KCNH2, RYR2, SCN1A
  GO:0030001   Metal ion transport                         0.0003543     0.1974   CNGA2, CTNNB1, NALCN, KCNH5, GPR35, KCNH2, TRPV6, CHD7, RYR2, SCN1A, CDH23
  GO:0043269   Regulation of ion transport                 0.0003573     0.1974   CTNNB1, NALCN, KCNH5, GPR35, KCNH2, NLGN3, CHD7, RYR2, SCN1A

GO, Gene Ontology; ID, identification; FDR, false discovery rate.

###### 

Significantly enriched GO cellular component categories of the 68 mutated genes associated with smoking status.

  GO ID        Description                                      P-value       FDR      Overlap genes
  ------------ ------------------------------------------------ ------------- -------- ---------------------------------------------------------------------------------------------------------------------------------------------------
  GO:0030018   Z disc                                           4.49×10^−5^   0.0294   CTNNB1, FLNC, RYR2, SCN1A, TTN
  GO:0031674   I band                                           6.91E-05      0.0294   CTNNB1, FLNC, RYR2, SCN1A, TTN
  GO:0044459   Plasma membrane part                             0.000105      0.0297   CNGA2, CTNNB1, EGFR, ENPEP, SPATA13, PHLPP2, KCNH5, GPR35, HIP1, ATP13A5, KCNH2, NLGN3, TRPV6, TENM3, PCDHGB7, SCN1A, SPTA1, USH2A, PCDHGA8, SNPH
  GO:0030017   Sarcomere                                        0.00029       0.0572   CTNNB1, FLNC, RYR2, SCN1A, TTN
  GO:0042995   Cell projection                                  0.000359      0.0572   CNGA2, CTNNB1, CNTN4, DNAH9, SPATA13, PHLPP2, GLI2, TENM3, RPTOR, TSHZ3, CDH23, SPTA1, USH2A, DNAH11, SNPH
  GO:0044449   Contractile fiber part                           0.000456      0.0572   CTNNB1, FLNC, RYR2, SCN1A, TTN
  GO:0030016   Myofibril                                        0.000471      0.0572   CTNNB1, FLNC, RYR2, SCN1A, TTN
  GO:0043292   Contractile fiber                                0.000588      0.0625   CTNNB1, FLNC, RYR2, SCN1A, TTN
  GO:0030122   AP-2 adaptor complex                             0.000942      0.0801   EGFR, HIP1
  GO:0030128   Clathrin coat of endocytic vesicle               0.000942      0.0801   EGFR, HIP1
  GO:0098590   Plasma membrane region                           0.001172      0.0906   CNGA2, CTNNB1, EGFR, ENPEP, SPATA13, PHLPP2, HIP1, NLGN3, USH2A, SNPH
  GO:0030132   Clathrin coat of coated pit                      0.001618      0.1146   EGFR, HIP1
  GO:0097458   Neuron part                                      0.002216      0.1449   CNTN4, PHLPP2, HIP1, TENM3, RPTOR, TSHZ3, CDH23, SMARCA4, SPTA1, USH2A, SNPH
  GO:0090575   RNA polymerase II transcription factor complex   0.002476      0.1478   TAF1L, CTNNB1, MYF5
  GO:0005929   Cilium                                           0.003008      0.1478   CNGA2, DNAH9, PHLPP2, GLI2, USH2A, DNAH11
  GO:0043234   Protein complex                                  0.003037      0.1478   TAF1L, CTNNB1, DNAH9, EGFR, NUP205, COL6A5, HIP1, MYF5, RPTOR, RYR2, SMARCA4, TEAD1, TTN, USH2A, DNAH11, DEPDC5
  GO:0030125   Clathrin vesicle coat                            0.003127      0.1478   EGFR, HIP1
  GO:0031226   Intrinsic component of plasma membrane           0.003156      0.1478   CNGA2, ENPEP, KCNH5, GPR35, ATP13A5, KCNH2, NLGN3, TRPV6, TENM3, PCDHGB7, SCN1A, SPTA1, PCDHGA8
  GO:0031253   Cell projection membrane                         0.003305      0.1478   CNGA2, CTNNB1, SPATA13, PHLPP2, USH2A
  GO:0098858   Actin-based cell projection                      0.003565      0.1515   CTNNB1, SPATA13, CDH23, USH2A
  GO:0030131   Clathrin adaptor complex                         0.004254      0.1718   EGFR, HIP1
  GO:0031090   Organelle membrane                               0.004448      0.1718   CNGA2, EGFR, ENPEP, PHLPP2, NUP205, HIP1, MALRD1, RPTOR, RYR2, WBSCR17, DEPDC5, SNPH, TBC1D4, SEC16A
  GO:0044441   Ciliary part                                     0.004724      0.1746   CNGA2, DNAH9, PHLPP2, GLI2, USH2A
  GO:0044798   Nuclear transcription factor complex             0.005127      0.1816   TAF1L, CTNNB1, MYF5

GO, Gene Ontology; ID, identification; FDR, false discovery rate.

###### 

Significantly enriched GO molecular function categories of the 68 mutated genes associated with smoking status.

  GO ID        Description                                                  P-value       FDR      Overlap genes
  ------------ ------------------------------------------------------------ ------------- -------- -----------------------------------------------------------------------------------------------------
  GO:0044877   Macromolecular complex binding                               2.18×10^−5^   0.0308   CTNNB1, EGFR, FLNC, GLI2, HIP1, CHD7, RPTOR, TSHZ3, SMARCA4, SPTA1, TTN, USH2A, KDM8, BAZ1B, DEPDC5
  GO:0070577   Lysine-acetylated histone binding                            5.57E-05      0.0393   TAF1L, SMARCA4, BAZ1B
  GO:0005516   Calmodulin binding                                           9.33E-05      0.0418   CNGA2, EGFR, KCNH5, TRPV6, RYR2, TTN
  GO:0051015   Actin filament binding                                       0.000118      0.0418   EGFR, FLNC, HIP1, SPTA1, TTN
  GO:0005261   Cation channel activity                                      0.000273      0.0742   CNGA2, NALCN, KCNH5, KCNH2, TRPV6, RYR2, SCN1A
  GO:0003682   Chromatin binding                                            0.0004        0.0742   CTNNB1, EGFR, GLI2, CHD7, TSHZ3, SMARCA4, KDM8, BAZ1B
  GO:0000155   Phosphorelay sensor kinase activity                          0.000443      0.0742   KCNH5, KCNH2
  GO:0004673   Protein histidine kinase activity                            0.000443      0.0742   KCNH5, KCNH2
  GO:0046982   Protein heterodimerization activity                          0.000472      0.0742   CTNNB1, EGFR, KCNH5, HIP1, MYF5, TENM3, SPTA1
  GO:0005244   Voltage-gated ion channel activity                           0.000918      0.118    CNGA2, NALCN, KCNH5, KCNH2, SCN1A
  GO:0022832   Voltage-gated channel activity                               0.000918      0.118    CNGA2, NALCN, KCNH5, KCNH2, SCN1A
  GO:0016775   Phosphotransferase activity, nitrogenous group as acceptor   0.001053      0.1241   KCNH5, KCNH2
  GO:0005216   Ion channel activity                                         0.001884      0.1874   CNGA2, NALCN, KCNH5, KCNH2, TRPV6, RYR2, SCN1A
  GO:0046873   Metal ion transmembrane transporter activity                 0.001917      0.1874   CNGA2, NALCN, KCNH5, KCNH2, TRPV6, RYR2, SCN1A
  GO:0001159   Core promoter proximal region DNA binding                    0.001988      0.1874   GLI2, MYF5, CHD7, SMARCA4, TEAD1, ZNF536
  GO:0022838   Substrate-specific channel activity                          0.002202      0.1896   CNGA2, NALCN, KCNH5, KCNH2, TRPV6, RYR2, SCN1A
  GO:0008324   Cation transmembrane transporter activity                    0.002279      0.1896   CNGA2, NALCN, KCNH5, ATP13A5, KCNH2, TRPV6, RYR2, SCN1A
  GO:0022836   Gated channel activity                                       0.002541      0.1903   CNGA2, NALCN, KCNH5, KCNH2, RYR2, SCN1A
  GO:0032403   Protein complex binding                                      0.002557      0.1903   EGFR, FLNC, HIP1, RPTOR, SPTA1, TTN, USH2A, DEPDC5

GO, Gene Ontology; ID, identification; FDR, false discovery rate.
